This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Race Oncology – The tip of the spear in the race to beat cancer
Race Oncology CEO/MD Phil Lynch speaks to Matt Birney of the Bulls n’ Bears Report about Race’s latest results and outlook.
-
Race Extends Heart Protection Collaboration with University of Newcastle
10 December 2021 – Race Oncology Limited (“Race”) is pleased to announce it has extended and expanded its collaborative cardio-protective research program for Zantrene® (bisantrene dihydrochloride) with eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, at The University of Newcastle. This collaboration builds on the initial heart safety preclinical study (ASX announcement: 28…
-
Expanded Heart Protection Discovery for Zantrene
08 December 2021 – Race Oncology Limited (“Race”) is pleased to share additional interim results from the Zantrene® (bisantrene dihydrochloride) preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, in collaboration with cancer scientist Associate Professor Nikki Verrills, at The University of Newcastle (ASX announcement: 28 April…
-
Breakthrough Chemotherapy Heart Protection Discovery for Zantrene
22 November 2021 – Race Oncology Limited (“Race”) is pleased to share interim results from the Zantrene® preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, in collaboration with cancer scientist Associate Professor Nikki Verrills, at The University of Newcastle (ASX announcement: 28 April 2021). This research…
-
Race Initiates Strategic Zantrene Formulation Collaboration with the University of Wollongong
8 November 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a strategic collaborative research agreement with the University of Wollongong (UOW) to undertake preclinical evaluation of new Zantrene formulations designed by Race. This collaboration is expected to provide significant value to the company by expanding the market potential…